
    
      This study will evaluate overall physician-determined XIENCE V® Everolimus Eluting Coronary
      Stent system (XIENCE V®) acute performance, deliverability and resource utilization in the
      catheterization lab in the "real world" as used by a broad group of physicians at a variety
      of health care facilities. This study will include all consecutively enrolled patients in the
      United States of America (USA) who consent to participate and receive XIENCE V® stents.
    
  